Logo image of ACOR

ACORDA THERAPEUTICS INC (ACOR) Stock Fundamental Analysis

NASDAQ:ACOR - Nasdaq - US00484M7002 - Common Stock - Currency: USD

0.661  -0.22 (-24.86%)

After market: 0.5656 -0.1 (-14.43%)

Fundamental Rating

0

Overall ACOR gets a fundamental rating of 0 out of 10. We evaluated ACOR against 555 industry peers in the Biotechnology industry. ACOR may be in some trouble as it scores bad on both profitability and health. ACOR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

ACOR had negative earnings in the past year.
ACOR had a negative operating cash flow in the past year.
In the past 5 years ACOR always reported negative net income.
ACOR had a negative operating cash flow in each of the past 5 years.
ACOR Yearly Net Income VS EBIT VS OCF VS FCFACOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M -200M

1.2 Ratios

ACOR has a worse Return On Assets (-233.00%) than 90.78% of its industry peers.
Industry RankSector Rank
ROA -233%
ROE N/A
ROIC N/A
ROA(3y)-90.83%
ROA(5y)-64.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACOR Yearly ROA, ROE, ROICACOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

Looking at the Gross Margin, with a value of 86.92%, ACOR belongs to the top of the industry, outperforming 90.61% of the companies in the same industry.
ACOR's Gross Margin has improved in the last couple of years.
ACOR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.92%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y1.97%
ACOR Yearly Profit, Operating, Gross MarginsACOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

0

2. Health

2.1 Basic Checks

ACOR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACOR has been increased compared to 1 year ago.
Compared to 5 years ago, ACOR has more shares outstanding
The debt/assets ratio for ACOR is higher compared to a year ago.
ACOR Yearly Shares OutstandingACOR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
ACOR Yearly Total Debt VS Total AssetsACOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

ACOR has an Altman-Z score of -16.36. This is a bad value and indicates that ACOR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.36, ACOR is doing worse than 83.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.36
ROIC/WACCN/A
WACC5.57%
ACOR Yearly LT Debt VS Equity VS FCFACOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.33 indicates that ACOR may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.33, ACOR is doing worse than 96.42% of the companies in the same industry.
A Quick Ratio of 0.26 indicates that ACOR may have some problems paying its short term obligations.
The Quick ratio of ACOR (0.26) is worse than 97.61% of its industry peers.
Industry RankSector Rank
Current Ratio 0.33
Quick Ratio 0.26
ACOR Yearly Current Assets VS Current LiabilitesACOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

0

3. Growth

3.1 Past

ACOR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -129.75%.
The Revenue has decreased by -0.77% in the past year.
Measured over the past years, ACOR shows a very negative growth in Revenue. The Revenue has been decreasing by -24.24% on average per year.
EPS 1Y (TTM)-129.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1202.02%
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y-8.39%
Revenue growth 5Y-24.24%
Sales Q2Q%20.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACOR Yearly Revenue VS EstimatesACOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M
ACOR Yearly EPS VS EstimatesACOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 0 -50 -100 -150 -200

1

4. Valuation

4.1 Price/Earnings Ratio

ACOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACOR Price Earnings VS Forward Price EarningsACOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ACOR is valued cheaply inside the industry as 97.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.69
ACOR Per share dataACOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 -100 -150 -200

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ACOR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ACORDA THERAPEUTICS INC

NASDAQ:ACOR (4/11/2024, 8:00:01 PM)

After market: 0.5656 -0.1 (-14.43%)

0.661

-0.22 (-24.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-07 2024-03-07/amc
Earnings (Next)05-02 2024-05-02/amc
Inst Owners0.49%
Inst Owner Change0%
Ins Owners44.4%
Ins Owner Change0%
Market Cap821.03K
Analysts82.86
Price Target10.2 (1443.12%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 8.69
EPS(TTM)-204.57
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-11.47
FCFYN/A
OCF(TTM)-11.26
OCFYN/A
SpS94.75
BVpS-127.17
TBVpS-145.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -233%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.92%
FCFM N/A
ROA(3y)-90.83%
ROA(5y)-64.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.66%
GM growth 5Y1.97%
F-Score4
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 0.83%
Cap/Sales 0.22%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.33
Quick Ratio 0.26
Altman-Z -16.36
F-Score4
WACC5.57%
ROIC/WACCN/A
Cap/Depr(3y)0.58%
Cap/Depr(5y)54.73%
Cap/Sales(3y)0.15%
Cap/Sales(5y)10.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-129.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1202.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-0.77%
Revenue growth 3Y-8.39%
Revenue growth 5Y-24.24%
Sales Q2Q%20.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y61.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y32.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.09%
OCF growth 3YN/A
OCF growth 5YN/A